|
1.
|
Furnari FB, Fenton T, Bachoo RM, et al:
Malignant astrocytic glioma: genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Grossman SA, Ye X, Piantadosi S, et al:
Survival of patients with newly diagnosed glioblastoma treated with
radiation and temozolomide in research studies in the United
States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ulasov IV, Zhu ZB, Tyler MA, et al:
Survivin-driven and fiber-modified oncolytic adenovirus exhibits
potent antitumor activity in established intracranial glioma. Hum
Gene Ther. 18:589–602. 2007. View Article : Google Scholar
|
|
4.
|
Chiocca EA, Abbed KM, Tatter S, et al: A
phase I open label, dose-escalation, multi-institutional trial of
injection with an E1B-attenuated adenovirus, ONYX-015, into the
peritumoral region of recurrent malignant gliomas, in the adjuvant
setting. Mol Ther. 10:958–966. 2004. View Article : Google Scholar
|
|
5.
|
Yazaki T, Manz HJ, Rabkin SD and Martuza
EL: Treatment of human malignant meningiomas by G207, a
replication-competent multimutated herpes simplex virus 1. Cancer
Res. 55:4752–4756. 1995.PubMed/NCBI
|
|
6.
|
Markert JM, Medlock MD, Rabkin SD, et al:
Conditionally replicating herpes simplex virus mutant, G207 for the
treatment of malignant glioma: results of a phase I trial. Gene
Ther. 7:867–874. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Sonabend AM, Ulasov IV and Lesniak MS:
Gene therapy trials for the treatment of high-grade gliomas. Gene
Ther Mol Biol. 11:79–92. 2007.PubMed/NCBI
|
|
8.
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chakravarti A, Noll E, Black PM,
Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS:
Quantitatively determined survivin expression levels are of
prognostic value in human gliomas. J Clin Oncol. 20:1063–1068.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Van Houdt WJ, Haviv YS, Lu B, et al: The
human survivin promoter: a novel transcriptional targeting strategy
for treatment of glioma. J Neurosurg. 104:583–592. 2006.PubMed/NCBI
|
|
11.
|
Ulasov IV, Rivera AA, Sonabend AM, Rivera
LB, Wang M, Zhu ZB and Lesniak MS: Comparative evaluation of
survivin, midkine, and CXCR4 promoters for transcriptional
targeting of glioma gene therapy. Cancer Biol Ther. 6:679–685.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Asaoka K, Tada M, Sawamura Y, Ikeda J and
Abe H: Dependence of efficient adenoviral gene delivery in
malignant glioma cells on the expression levels of the
Coxsackievirus and adenovirus receptor. J Neurosurg. 92:1002–1008.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Nandi S, Ulasov IV, Rolle CE, Han Y and
Lesniak MS: A chimeric adenovirus with an Ad 3 fiber knob
modification augments glioma virotherapy. J Gene Med. 11:1005–1011.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Segerman A, Atkinson JP, Marttila M,
Dennerquist V, Wadell G and Arnberg N: Adenovirus type 11 uses CD46
as a cellular receptor. J Virol. 77:9183–9191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Gaggar A, Shayakhmetov DM and Lieber A:
CD46 is a cellular receptor for group B adenoviruses. Nat Med.
9:1408–1412. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sirena D, Lilienfeld B, Eisenhut M, et al:
The human membrane cofactor CD46 is a receptor for species B
adenovirus serotype 3. J Virol. 78:4454–4462. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fleischli C, Sirena D, Lesage G, Havenga
MJ, Cattaneo R, Greber UF and Hemmi S: Species B adenovirus
serotypes 3, 7, 11 and 35 share similar binding sites on the
membrane cofactor protein CD46 receptor. J Gen Virol. 88:2925–2934.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gustafsson DJ, Andersson EK, Hu YL,
Marttila M, Lindman K and Strand M: Adenovirus 11p downregulates
CD46 early in infection. Virology. 405:474–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Zhu ZB, Makhija SK, Lu B, et al:
Incorporating the survivin promoter in an infectivity enhanced
CRAd-analysis of oncolysis and antitumor effects in vitro
and in vivo. Int J Oncol. 27:237–246. 2005.PubMed/NCBI
|
|
20.
|
Xia H, Anderson B, Mao Q and Davidson BL:
Recombinant human adenovirus: targeting to the human transferrin
receptor improves gene transfer to brain microcapillary
endothelium. J Virol. 74:11359–11366. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Li X, Liu S, Wang D, Chen H and Xia H:
Adenoviral delivered eGFP-intron splicing system for multiple gene
RNAi. Biotechnol Lett. 33:1723–1728. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhang KJ, Wang YG, Cao X, et al: Potent
antitumor effect of interleukin-24 gene in the survivin promoter
and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene
Ther. 20:818–830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Chen W, Wu Y, Liu W, et al: Enhanced
antitumor efficacy of a novel fiber chimeric oncolytic adenovirus
expressing p53 on hepatocellular carcinoma. Cancer Lett.
307:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Xiao LL, Wu YM, Qian J, et al: The
antitumor efficacy of IL-24 mediated by E1A and E1B triple
regulated oncolytic adenovirus. Cancer Biol Ther. 10:242–250. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Bortolanza S, Bunuales M, Otano I, et al:
Treatment of pancreatic cancer with an oncolytic adenovirus
expressing interleukin-12 in Syrian hamsters. Mol Ther. 17:614–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wohlfahrt ME, Beard BC, Lieber A and Kiem
HP: A capsid-modified, conditionally replicating oncolytic
adenovirus vector expressing TRAIL leads to enhanced cancer cell
killing in human glioblastoma models. Cancer Res. 67:8783–8790.
2007. View Article : Google Scholar
|
|
27.
|
Zhu ZB, Makhija SK, Lu B, et al:
Transcriptional targeting of tumors with a novel tumor-specific
survivin promoter. Cancer Gene Ther. 11:256–262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC
and Lesniak MS: Oncolytic adenoviral vectors which employ the
survivin promoter induce glioma oncolysis via a process of
beclin-dependent autophagy. Int J Oncol. 34:729–742.
2009.PubMed/NCBI
|
|
29.
|
Fuxe J, Liu L, Malin S, Philipson L,
Collins VP and Pettersson RF: Expression of the coxsackie and
adenovirus receptor in human astrocytic tumors and xenografts. Int
J Cancer. 103:723–729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Silver J and Mei YF: Transduction and
oncolytic profile of a potent replication-competent adenovirus 11p
vector (RCAd11pGFP) in colon carcinoma cells. Plos One.
6:e175322011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Brouwer E, Havenga MJ, Ophorst O, et al:
Human adenovirus type 35 vector for gene therapy of brain cancer:
improved transduction and bypass of pre-existing anti-vector
immunity in cancer patients. Cancer Gene Ther. 14:211–219. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Wang H, Li ZY, Liu Y, et al: Desmoglein 2
is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med.
17:96–104. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Allen C, McDonald C, Giannini C, Peng KW,
Rosales G, Russell SJ and Galanis E: Adenoviral vectors expressing
fusogenic membrane glycoproteins activated via matrix
metalloproteinase cleavable linkers have significant antitumor
potential in the gene therapy of gliomas. J Gene Med. 6:1216–1227.
2004. View
Article : Google Scholar
|
|
34.
|
Mäenpää A, Junnikkala S, Hakulinen J,
Timonen T and Meri S: Expression of complement membrane regulators
membrane cofactor protein (CD46), decay accelerating factor (CD55),
and protectin (CD59) in human malignant gliomas. Am J Pathol.
148:1139–1152. 1996.
|
